Immunexpress Receives Notice of U.S. Patent Allowance for SeptiCyte™ Technology to Quantify Biomarkers

The allowance complements the Company's growing patent portfolio of gene technology in the detection of host response to sepsis

News provided by

Immunexpress Inc.

Jul 26, 2018, 08:00 ET

SEATTLE, July 26, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 15/160749, "Validating biomarker measurement," which relates to methods used in quantification of biomarkers of its SeptiCyte™ technology.

"This patent application covers an aspect of our SeptiCyte™ technology to measure biomarker levels in whole-blood samples of patients suspected of having sepsis," commented Rolland D. Carlson, PhD, Chief Executive Officer of Immunexpress. "Additionally, it strengthens the position of Immunexpress by putting us at the forefront of host response analysis development within sepsis diagnostics. The uniqueness of the SeptiCyte™ technology is further underlined by the allowance of this patent application."

Annually, sepsis affects an estimated 20-30 million people worldwideⁱ and represents a major unmet medical need. According to the Agency for Healthcare Research and Quality, sepsis is the most expensive condition treated in U.S. hospitals, costing more than $20 billion in 2011 and increasing annually by 11.9%ⁱⁱ, on average.

Immunexpress has been an early leading innovator in developing whole-blood, host gene expression biomarkers for differentiating systemic inflammatory conditions caused by infectious and non-infectious agents, resulting in the FDA clearance for SeptiCyte™ LAB in early 2017.

This patent application protects methods used in quantifying biomarker levels in whole blood samples, adding to the current Immunexpress portfolio of 14 patent families, to date of which three have been granted in the U.S. It significantly enhances Immunexpress' claims of the SeptiCyte™ technology, in particular, its application on the Biocartis Idylla™¹ platform, which aims to rapidly provide clinicians with diagnostic information to aid in differentiating sepsis and non-infectious systemic inflammation (SIRS).

About Immunexpress

Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients suspected of sepsis. Immunexpress' SeptiCyte™ technology rapidly quantifies, directly from whole blood, specific molecular markers from the patient's own immune system – the 'host response'. SeptiCyte™ LAB, recently cleared by the FDA, is the first of its kind in using the host immune system to differentiate systemic inflammatory response syndrome (SIRS) and sepsis. Detecting the host's response to infection has the potential to differentiate infection earlier, faster and more accurately than finding the invading pathogen because it is independent of whether or not the pathogen is present in the sample. Immunexpress' pipeline includes several sample-to-answer assays for near-patient testing.

For more information visit http://www.immunexpress.com/.

Follow Immunexpress on Twitter and LinkedIn.

Media Contacts:
Maggie Beller
Russo Partners, LLC
(646) 942-5631
[email protected]

1 Idylla™ is a registered trademark of the Biocartis Group.
___________________________________________

i World Sepsis Day Factsheet 2018, available at www.world-sepsis-day.org.
ii Torio and Andrews, "National Inpatient Hospital Costs: The Most Expensive Conditions by Payer", 2011: Statistical Brief #160. In: "Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, Rockville (MD)": Agency for Health Care Policy and Research (US) 2006-2013.

SOURCE Immunexpress Inc.